Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.